To initially evaluate the cytotoxicity of CD19-NK-92 and CD138-NK-92 cells, human ALL-derived REH cells, which expressed both CD19 and CD138 surface antigens, were chosen. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.